April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. This cutting-edge mobile solution is designed to revolutionize cardiac care by directly providing state-of-the-art cardiac PET/CT imaging services to medical facilities on their schedule.
April 23, 2024 — A recent study designed and implemented by investigators at Cedars-Sinai found that artificial intelligence (AI) can accurately evaluate cardiovascular risk during a routine chest computed tomography (CT) scan without contrast.
April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management.
April 22, 2024 — A new study showed that a non-invasive imaging test can help identify patients with coronary artery blockage or narrowing who need a revascularization procedure.
April 22, 2024 — At the annual American College of Cardiology conference (ACC.24) in Atlanta last week, RCE Technologies, Inc., (RCE), an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection, highlighted results of a pilot study enrolling cardiac catheterization patients in the first-ever human
April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the recent release of V-Wave's RELIEVE-HF trial data supporting the evidence base around atrial shunt therapy, which is currently under study in the globalÂ
April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period immediately after atrial fibrillation (AF) ablation, when early occurrences of AF are thought not to predict long-term AF recurrence.
April 18, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the AB-1002 program.
